Friday 6 November 2026 Export HIMS’s income statement to Excel — free account

Hims & Hers Health, Inc.

HIMS Healthcare Drug Manufacturers Specialty & Generic

Hims & Hers Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 59.0% from fiscal 2024.

Revenue: +38.3%
EPS: −294.7%
Free cash flow: +5.09%
Total debt: +40.8%

Quarter to June 2026, against a year earlier

24.11 2.55 −9.56%

Follow HIMS

Alert me

Market cap: $5.6B
P/E: 0.0×
Fwd P/E: −49.4×
Dividend yield: —
F-score: 4/9
Altman Z: 4.10
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Hims & Hers Health, Inc. (HIMS) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, Hims & Hers Health, Inc. (HIMS) trades at a price to free cash flow of 67.3×. Over the past ten years it has ranged from 0.0× (June 2023) to 112× (July 2025); the current reading is higher than 80% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 16.3× and above the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/HIMS/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="Hims &amp; Hers Health, Inc. price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/HIMS/metrics/price-to-free-cash-flow">Hims &amp; Hers Health, Inc. (HIMS) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	98.8×	296.13%
FY2024	24.9×	(30.49%)
FY2023	35.9×	—
FY2022	0.0×	—
FY2022	0.0×	—
FY2021	0.0×	—
FY2021	0.0×	—
FY2020	0.0×	—
FY2020	0.0×	—
FY2019	0.0×	—

Period	Price to free cash flow	Change
Jun 2026	96.8×	62.71%
Mar 2026	59.5×	(39.78%)
Dec 2025	98.8×	3.01%
Sep 2025	95.9×	13.47%
22 more quarters	Free account

Against its own ten years

Low 0.0× High 112×

Ten-year median 0.0×

Current reading's percentile 80

Company	Price to free cash flow
AMRX AMNEAL PHARMACEUTICALS, INC. compare	n/m
AMLX Amylyx Pharmaceuticals, Inc. compare	n/m
LNTH Lantheus Holdings, Inc. compare	16.9×
LQDA Liquidia Corporation compare	26.4×
ALKS Alkermes plc compare	32.8×
KNSA Kiniksa Pharmaceuticals International, plc compare	35.1×
HIMS Hims & Hers Health, Inc.	67.3×
SUPN Indivior Pharmaceuticals Inc. compare	115×
RDY Dr. Reddy's Laboratories Ltd compare	126×
Drug Manufacturers Specialty & Generic industry median	16.3×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

Hims & Hers Health, Inc. (HIMS) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on HIMS

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on HIMS

Stockrow Weekly